The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.a

Pulmonary edema, noncardiogenic (NCPE)

Publications

Blasco MR, Ramos A, Malo CG, García-Merino A

Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.

Journal of neurology. 2017;264(1):168-169

Grable B, Sakai T

Isolated left-sided pulmonary edema caused by alemtuzumab (Campath) during kidney transplantation.

Transplant international : official journal of the European Society for Organ Transplantation. 2010;23(8):851-4